ADIPOQ and schizophrenia: Given the prior evidence consistent with cardiac inflammation in schizophrenia [10], we hypothesised that there would be lower levels of adiponectin and elevated glucoregulatory and inflammatory markers consistent with activation of the non-hypertensive pathway in patients with schizophrenia.